Background/Aims: Hepatocellular carcinoma (HCC), which is the third most common cancer in Korea, has a very poor prognosis. However, only a few studies have performed a comprehensive survival-related analysis in all patients who were consecutively diagnosed and treated over a given period of time. The aim of this study was to determine the 5-year survival rate and its prognostic factors among HCC patients. Methods: In total, 257 patients who were consecutively diagnosed with HCC between January 2000 and December 2003 were followed until death or until December 2008. We analyzed their survival outcomes according to their clinical characteristics, tumor staging, and treatment modalities, and determined the independent prognostic factors affecting survival. Results: The patients were aged 59±10 years (mean±SD). During the follow-up period, 223 patients (86.8%) died and the overall median survival was 10.8 months; the 1-, 3-, and 5-year survival rates were 44.4%, 21.0%, and 12.1%, respectively. The outcomes in patients with tumor node metastasis (TNM) stage I or II and Child-Pugh class A or B were significantly better with surgical resection than with other treatment modalities (P<0.01). Patients who underwent supplementary transcatheter arterial chemoembolization as a second-line treatment after surgical resection had better outcomes than those who underwent surgical resection alone (P=0.02). Initial symptoms, Child-Pugh class, serum alpha-fetoprotein, tumor size, portal vein thrombosis, and TNM stage were found to be independent prognostic factors for survival among HCC patients. Conclusions: This retrospective cohort study elucidated survival outcomes and prognostic factors affecting survival in HCC patients at a single center. 
INTRODUCTION
Hepatocellular carcinoma (HCC), which shows a grave morbidity and mortality, is the third most common malignancy following stomach and lung cancers in Korea.
1,2 HCC has a very poor prognosis in comparison with other solid tumors because HCC rapidly progresses with its aggressive biological behavior and is usually diagnosed at an advanced stage.
Furthermore, the majority of HCC develops in the background of chronic liver diseases such as liver cirrhosis, which makes a curative treatment more difficult. 3 Nevertheless, the 5-year survival rate of HCC has slightly improved from 11.0% in 1993-1997 to 14 .7% in 1998-2002 in Korea, 4 and several large-scale studies have also reported modest improvements in the survival of HCC patients worldwide during the last few decades. 5, 6 It is expected that the survival rates of HCC patients will continue to increase with strict application of screening/surveillance programs using alpha-fetoprotein 
PATIENTS AND METHODS

Patients
RESULTS
Baseline characteristics
Baseline characteristics are summarized in Fig. 2D ). (Table 4) .
Survival according to treatment modalities
DISCUSSION
Despite the high prevalence and mortality of HCC in Korea, few studies have stratified the survival outcomes according to liver functions, tumor stages, and treatment modalities in a cohort of HCC patients. 14 Most studies released limited reports about survival outcomes in HCC patients who underwent a certain therapy. 16, 17 In this study, clinical data were collected from all patients who were treated and followed at a single center for a given period of time and analyzed according to the clinical staging system and treatment modalities proposed by the Korea Liver
Cancer Study Group and the National Cancer Center. 18 We However, this is a single-center study, and liver transplantation was not available in our institution during this study period, which is possibly a limiting factor with respect to generalizing these results.
In summary, we identified the clinical characteristics, survival rates, and independent prognostic factors affecting survival in a retrospective cohort of HCC patients. This cohort analysis may provide useful information of prognosis predictability in HCC patients, especially for a prospective cohort study in the future.
